Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has completed and commissioned a new high containment facility for potent product manufacture at its Edinburgh, UK site, Macfarlan Smith. Macfarlan Smith is a provider of opiates, controlled substance and highly potent products; the new self-contained, state-of-the-art facility is required to meet existing demand for potent products and also provides additional capacity ...